e-Therapeutics PLC | Mutual Funds
Mutual Funds that own e-Therapeutics PLC
Invesco Perpetual UK Invt. Ser. - High Income
46,414,676
17.28%
0
0.04%
03/29/2018
CF Woodford Equity Income
36,918,214
13.74%
0
0.05%
07/31/2018
Invesco Perpetual UK 2 Invt. Series - Income Fund
35,323,680
13.15%
0
0.06%
03/29/2018
St. James's Place Unit Trust - UK High Income
9,394,579
3.5%
0
0.05%
03/31/2018
Henderson Invt. Fds. Series I - UK & Irish Smaller Companies
8,427,438
3.14%
0
0.39%
07/31/2018
Invesco Perpetual UK Equity Pension Fund
2,785,704
1.04%
0
0.07%
03/29/2018
Old Mutual Woodford Equity Income Fund
1,004,686
0.37%
0
0.05%
07/31/2018
| Address |
17 Blenheim Office Park
Long Hanborough Oxfordshire OX29 8LN
United Kingdom
|
|
Employees
|
- |
| Website |
http://etherapeutics.co.uk |
| Updated |
07/08/2019 |
| e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. It focuses on the therapeutic immune-oncology, addressing drug resistance in targeted cancer therapies and antivirals. It offers the following variety of preclinical stage assets: ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFa; ETS2400, Hedgehog pathway inhibition; and ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects. |
